• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc.

    11/13/24 4:30:24 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COLL alert in real time by email
    SC 13G/A 1 tm2427812d6_sc13ga.htm SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G/A

     

     

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 4)*

     

    Collegium Pharmaceutical, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    19459J104

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of event which requires filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    (Page 1 of 7 Pages)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     

     

    CUSIP No. 19459J104

     

    13G/A Page 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Rubric Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,250,000 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,250,000 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,250,000 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.88%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. 19459J104

     

    13G/A Page 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    David Rosen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,250,000 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,250,000 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,250,000 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.88%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

    CUSIP No. 19459J104

     

    13G/A Page 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Collegium Pharmaceutical, Inc. (the "Issuer").
       
    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Issuer's principal executive offices are located at 100 Technology Center Drive, Suite 300, Stoughton, MA 02072.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the shares of Common Stock (as defined in Item 2(d) below) reported herein; and
         
      (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.
       
    Item 2(c). CITIZENSHIP:
       
      Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.
       
    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common stock, $0.001 par value per share (the "Common Stock").
       
    Item 2(e). CUSIP NUMBER:
       
      19459J104

     

     

     

     

    CUSIP No. 19459J104

     

    13G/A Page 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
           
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
           
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
           
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
           
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
           
      (g) x Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
           
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:                                       

       
    Item 4. OWNERSHIP.
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 32,213,751 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission on August 8, 2024.

       
    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x
       
    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2. 
       
    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

     

     

     

    CUSIP No. 19459J104

     

    13G/A Page 6 of 7 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.
       
    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.
       
    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 19459J104

     

    13G/A Page 7 of 7 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATED: November 13, 2024  
       
    RUBRIC CAPITAL MANAGEMENT LP  
       
    By: /s/ Michael Nachmani  
    Name: Michael Nachmani  
    Title: Chief Operating Officer  
       
    /s/ David Rosen  
    DAVID ROSEN  

     

     

     

    Get the next $COLL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COLL

    DatePrice TargetRatingAnalyst
    1/10/2025$46.00Hold → Buy
    Needham
    7/30/2024$47.00Neutral → Buy
    H.C. Wainwright
    6/7/2024$41.00 → $44.00Hold → Buy
    Jefferies
    5/10/2024Buy → Hold
    Needham
    5/10/2024$39.00Overweight → Neutral
    Piper Sandler
    1/4/2024$30.00 → $37.00Buy → Hold
    Jefferies
    8/25/2023$35.00 → $36.00Buy
    Needham
    5/2/2023$30.00Buy
    Jefferies
    More analyst ratings

    $COLL
    SEC Filings

    See more
    • Collegium Pharmaceutical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      5/19/25 4:05:20 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.

      SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      5/14/25 4:04:49 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical Inc. filed SEC Form 8-K: Other Events

      8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      5/12/25 8:10:35 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Collegium Pharmaceutical upgraded by Needham with a new price target

      Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00

      1/10/25 8:00:15 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00

      7/30/24 6:32:12 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical upgraded by Jefferies with a new price target

      Jefferies upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $44.00 from $41.00 previously

      6/7/24 7:29:08 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Collegium to Participate in Upcoming Investor Conferences

      STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro & Ophthalmology Summit 2025Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET Jefferies Global Healthcare ConferencePresentation: Thursday, June 5, 2025, at 1:25 p.m. ET The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharm

      5/19/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Announces $25 Million Accelerated Share Repurchase Program

      STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $65 million remaining under the program. "Collegium is off to a strong start in 2025 with first quarter revenues g

      5/12/25 8:05:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer

      5/8/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Announces Updates to its Board of Directors and Executive Leadership Team

             – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C

      3/17/25 7:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Appoints Nancy S. Lurker to its Board of Directors

      STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. "Collegium is pleased to welcome Nancy to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions." "This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth

      2/5/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fallon John A. was granted 9,791 shares, increasing direct ownership by 18% to 64,634 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      5/19/25 5:43:54 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lurker Nancy was granted 9,791 shares, increasing direct ownership by 77% to 22,517 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      5/19/25 5:43:15 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bohlin Garen G was granted 9,791 shares, increasing direct ownership by 19% to 62,259 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      5/19/25 5:42:47 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Collegium Pharmaceutical Inc.

      SC 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      11/13/24 5:13:28 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc.

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      11/13/24 4:30:24 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/14/24 12:04:28 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Financials

    Live finance-specific insights

    See more
    • Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer

      5/8/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

      STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Compa

      4/24/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

      – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; Repurchased $60.0 Million in Shares in 2024 – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON,

      2/27/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care